Pharmacy Practice Act; extend repealer on and make various changes in.
SB 2795 is a comprehensive update and reenactment of the Mississippi Pharmacy Practice Act. It extends the act’s repealer date to July 1, 2029, and revises a wide range of provisions governing the State Board of Pharmacy, pharmacist licensure, pharmacy permits, nonresident pharmacies, drug supply-chain entities, home medical equipment suppliers, and the prescription monitoring program. The bill also updates statutory definitions, including definitions for pharmacy services administrative organizations, interns/externs, registrants, reverse distributors, and related terms used throughout the chapter.
The bill expands and clarifies the Board of Pharmacy’s regulatory authority. It authorizes the board to delegate powers to its executive director, regulate pharmacy services administrative organizations, inspect a broader set of facilities in the drug supply chain, issue subpoenas during investigations, and order summary suspensions when there is an immediate danger to the public. It also broadens disciplinary coverage to include interns/externs, pharmacy technicians, registrants, and permit holders, while revising appeal procedures and monetary penalty provisions. In addition, it increases certain fees and surcharges, including the surcharge used to fund programs for impaired pharmacists and pharmacy students, and raises maximum permit fees for some entities.
The bill’s impact on state law is substantial because it modernizes licensing and oversight rules across the pharmacy sector. It requires broader registration or permitting for out-of-state pharmacies that provide pharmacy services to Mississippi residents, for entities in the prescription drug supply chain, and for businesses involved in home medical equipment or outdated drug returns. It also updates the prescription monitoring program to cover controlled substances and certain medical cannabis dispensing information, requires pharmacists and certain practitioners to register as PMP users, and changes reporting to the Legislature from an annual report to a report provided upon request that identifies opioid prescription counts.
Overall sentiment from the bill text and available context appears neutral to supportive of stronger regulation and modernization, with no recorded committee transcript or vote history indicating opposition. The measure reads as a technical and policy update intended to keep the pharmacy regulatory framework current, improve enforcement tools, and address newer industry structures such as pharmacy services administrative organizations and expanded supply-chain participants. Because there is no recorded debate in the provided materials, there is no documented public controversy in the available record.
The main points of potential contention are the bill’s expansion of regulatory reach and enforcement authority. Those affected may include pharmacies, nonresident pharmacies, wholesalers, manufacturers, repackagers, reverse distributors, pharmacy benefit managers, pharmacy services administrative organizations, home medical equipment suppliers, and pharmacists or technicians subject to discipline. Possible concerns include higher fees, broader inspection and subpoena powers, confidentiality exemptions for investigative committee records, and the ability to impose summary suspensions without a prior hearing in emergency situations.
SB 2795 would reenact and amend the Mississippi Pharmacy Practice Act, extending its sunset date to 2029 and revising numerous provisions in Title 73, Chapter 21 of the Mississippi Code. It broadens the State Board of Pharmacy’s authority over licensure, permits, inspections, discipline, investigations, and prescription monitoring, while also updating fee schedules, penalty ranges, and reporting requirements. The bill affects pharmacists, interns/externs, technicians, registrants, permit holders, nonresident pharmacies, supply-chain businesses, home medical equipment suppliers, and pharmacy-related administrative organizations.
No committee transcript or vote history was provided, so there is no recorded floor or committee debate to measure. Based on the bill text, the measure appears generally administrative and regulatory in nature, aimed at updating and strengthening pharmacy oversight rather than changing policy direction in a controversial way. The available context suggests a neutral-to-supportive posture, with the bill framed as a modernization and continuation of existing pharmacy law.
The most notable potential areas of contention are the bill’s expanded regulatory and enforcement powers. These include broader inspection authority over supply-chain facilities, subpoena power in investigations, confidentiality for investigative committee records, summary suspension authority without a hearing in emergencies, and increased fees and penalties. Entities most likely to be affected or to scrutinize the bill include pharmacies, nonresident pharmacies, wholesalers, manufacturers, pharmacy benefit managers, pharmacy services administrative organizations, reverse distributors, and home medical equipment suppliers.